Literature DB >> 30206799

Patterns of Grey Matter Atrophy at Different Stages of Parkinson's and Alzheimer's Diseases and Relation to Cognition.

Jonas Kunst1,2, Radek Marecek2, Patricia Klobusiakova1,2, Zuzana Balazova2, Lubomira Anderkova2, Nela Nemcova-Elfmarkova2, Irena Rektorova3,4.   

Abstract

Using MRI, a characteristic pattern of grey matter (GM) atrophy has been described in the early stages of Alzheimer's disease (AD); GM patterns at different stages of Parkinson's disease (PD) have been inconclusive. Few studies have directly compared structural changes in groups with mild cognitive impairment (MCI) caused by different pathologies (AD, PD). We used several analytical methods to determine GM changes at different stages of both PD and AD. We also evaluated associations between GM changes and cognitive measurements. Altogether 144 subjects were evaluated: PD with normal cognition (PD-NC; n = 23), PD with MCI (PD-MCI; n = 24), amnestic MCI (aMCI; n = 27), AD (n = 12), and age-matched healthy controls (HC; n = 58). All subjects underwent structural MRI and cognitive examination. GM volumes were analysed using two different techniques: voxel-based morphometry (VBM) and source-based morphometry (SBM), which is a multivariate method. In addition, cortical thickness (CT) was evaluated to assess between-group differences in GM. The cognitive domain z-scores were correlated with GM changes in individual patient groups. GM atrophy in the anterior and posterior cingulate, as measured by VBM, in the temporo-fronto-parietal component, as measured by SBM, and in the posterior cortical regions as well as in the anterior cingulate and frontal region, as measured by CT, differentiated aMCI from HC. Major hippocampal and temporal lobe atrophy (VBM, SBM) and to some extent occipital atrophy (SBM) differentiated AD from aMCI and from HC. Correlations with cognitive deficits were present only in the AD group. PD-MCI showed greater GM atrophy than PD-NC in the orbitofrontal regions (VBM), which was related to memory z-scores, and in the left superior parietal lobule (CT); more widespread limbic and fronto-parieto-occipital neocortical atrophy (all methods) differentiated this group from HC. Only CT revealed subtle GM atrophy in the anterior cingulate, precuneus, and temporal neocortex in PD-NC as compared to HC. None of the methods differentiated PD-MCI from aMCI. Both MCI groups showed distinct limbic and fronto-temporo-parietal neocortical atrophy compared to HC with no specific between-group differences. AD subjects displayed a typical pattern of major temporal lobe atrophy which was associated with deficits in all cognitive domains. VBM and CT were more sensitive than SBM in identifying frontal and posterior cortical atrophy in PD-MCI as compared to PD-NC. Our data support the notion that the results of studies using different analytical methods cannot be compared directly. Only CT measures revealed some subtle differences between HC and PD-NC.

Entities:  

Keywords:  Alzheimer’s disease; Cortical thickness; Mild cognitive impairment; Parkinson’s disease; Source-based morphometry; Voxel-based morphometry

Mesh:

Year:  2018        PMID: 30206799     DOI: 10.1007/s10548-018-0675-2

Source DB:  PubMed          Journal:  Brain Topogr        ISSN: 0896-0267            Impact factor:   3.020


  16 in total

1.  Altered brain activity in the bilateral frontal cortices and neural correlation with cognitive impairment in schizophrenia.

Authors:  Lingfang Yu; Lei Guo; Xinyu Fang; Fuyin Yang; Yan Chen; Yewei Wang; Dandan Wang; Zenan Wu; Ruimei Liu; Xing Tian; Chen Zhang
Journal:  Brain Imaging Behav       Date:  2021-08-27       Impact factor: 3.978

Review 2.  Morphological basis of Parkinson disease-associated cognitive impairment: an update.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2022-06-20       Impact factor: 3.850

Review 3.  Volume, density, and thickness brain abnormalities in mild cognitive impairment: an ALE meta-analysis controlling for age and education.

Authors:  Philip J Raine; Hengyi Rao
Journal:  Brain Imaging Behav       Date:  2022-04-13       Impact factor: 3.224

4.  Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.

Authors:  D M Vargas; M A De Bastiani; R B Parsons; F Klamt
Journal:  Mol Neurobiol       Date:  2020-11-19       Impact factor: 5.590

5.  Brain volumes and dual-task performance correlates among individuals with cognitive impairment: a retrospective analysis.

Authors:  Jason K Longhurst; Morgan A Wise; Daniel J Krist; Caitlin A Moreland; Jon A Basterrechea; Merrill R Landers
Journal:  J Neural Transm (Vienna)       Date:  2020-04-29       Impact factor: 3.575

Review 6.  Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways.

Authors:  Holly Green; Panagiota Tsitsi; Ioanna Markaki; Dag Aarsland; Per Svenningsson
Journal:  CNS Drugs       Date:  2019-02       Impact factor: 5.749

Review 7.  Gray Matter Changes in Parkinson's and Alzheimer's Disease and Relation to Cognition.

Authors:  Lenka Krajcovicova; Patricia Klobusiakova; Irena Rektorova
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-13       Impact factor: 5.081

8.  Brain MRI Reveals Ascending Atrophy in Parkinson's Disease Across Severity.

Authors:  Jamie C Blair; Matthew J Barrett; James Patrie; Joseph L Flanigan; Scott A Sperling; W Jeffrey Elias; T Jason Druzgal
Journal:  Front Neurol       Date:  2019-12-18       Impact factor: 4.003

9.  Aberrant cerebral perfusion pattern in amnestic mild cognitive impairment and Parkinson's disease with mild cognitive impairment: a comparative arterial spin labeling study.

Authors:  Song'an Shang; Jingtao Wu; Yu-Chen Chen; Hongri Chen; Hongying Zhang; Weiqiang Dou; Peng Wang; Xin Cao; Xindao Yin
Journal:  Quant Imaging Med Surg       Date:  2021-07

10.  Cortical thickness in Parkinson disease: A coordinate-based meta-analysis.

Authors:  LiQin Sheng; PanWen Zhao; HaiRong Ma; Joaquim Radua; ZhongQuan Yi; YuanYuan Shi; JianGuo Zhong; ZhenYu Dai; PingLei Pan
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.